Literature DB >> 26775602

Effects of Tongxinluo on myocardial fibrosis in diabetic rats.

Xiaomei Wang1, Changzheng Mu2, Tianchi Mu2, Lili Gao3, Yaxue Zhao3, Yangyi Zhang3, Zhimian Zhang4.   

Abstract

BACKGROUND: The aim of this study was to explore the effect of Tongxinluo on myocardial fibrosis in diabetic rats and its possible mechanism of action.
METHODS: Diabetic rat models were established and then divided into three groups: control, diabetes, and Tongxinluo groups. Heart function and myocardial interstitial collagen volume fraction were investigated, and the protein and mRNA expression levels of transforming growth factor beta 1 (TGF-β1), Smad3, and Smad7 were measured.
RESULTS: Heart function was clearly abnormal in the diabetes group compared with that in the control group, and the collagen volume fraction and mRNA expression levels of TGF-β1 and Smad3 were higher. However, the protein and mRNA expression levels of Smad7 were lower. In the Tongxinluo group, it was observed that these indicators were improved.
CONCLUSION: Tongxinluo was effective for the prevention and treatment of myocardial fibrosis in diabetic rats. It probably mediates the expressions of TGF-β1, Smad3, and Smad7 in rat cardiomyocytes to reduce the occurrence of myocardial fibrosis in diabetic rats.
Copyright © 2015. Published by Elsevier Taiwan LLC.

Entities:  

Keywords:  Smad(3); Smad(7); Tongxinluo; diabetic myocardial fibrosis; transforming growth factor beta 1

Mesh:

Substances:

Year:  2016        PMID: 26775602     DOI: 10.1016/j.jcma.2015.06.022

Source DB:  PubMed          Journal:  J Chin Med Assoc        ISSN: 1726-4901            Impact factor:   2.743


  5 in total

Review 1.  Research Progress of Traditional Chinese Medicine in Treatment of Myocardial fibrosis.

Authors:  Chunzhen Ren; Kai Liu; Xinke Zhao; Huan Guo; Yali Luo; Juan Chang; Xiang Gao; Xinfang Lv; Xiaodong Zhi; Xue Wu; Hugang Jiang; Qilin Chen; Yingdong Li
Journal:  Front Pharmacol       Date:  2022-06-08       Impact factor: 5.988

Review 2.  Panax ginseng C. A. Meyer as a potential therapeutic agent for organ fibrosis disease.

Authors:  Hao Liu; Chongning Lv; Jincai Lu
Journal:  Chin Med       Date:  2020-11-24       Impact factor: 5.455

3.  Effects of Dual-Dose Clopidogrel, Clopidogrel Combined with Tongxinluo Capsule, and Ticagrelor on Patients with Coronary Heart Disease and CYP2C19*2 Gene Mutation After Percutaneous Coronary Interventions (PCI).

Authors:  Shuxia Chen; Yi Zhang; Lili Wang; Yanping Geng; Jian Gu; Qingqing Hao; Hua Wang; Peng Qi
Journal:  Med Sci Monit       Date:  2017-08-07

4.  Inhibition of miR-128-3p by Tongxinluo Protects Human Cardiomyocytes from Ischemia/reperfusion Injury via Upregulation of p70s6k1/p-p70s6k1.

Authors:  Gui-Hao Chen; Chuan-Sheng Xu; Jie Zhang; Qing Li; He-He Cui; Xiang-Dong Li; Li-Ping Chang; Rui-Jie Tang; Jun-Yan Xu; Xia-Qiu Tian; Pei-Sen Huang; Jun Xu; Chen Jin; Yue-Jin Yang
Journal:  Front Pharmacol       Date:  2017-10-30       Impact factor: 5.810

5.  Potential Effectiveness of Chinese Patent Medicine Tongxinluo Capsule for Secondary Prevention After Acute Myocardial Infarction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Min Li; Chengyu Li; Shiqi Chen; Yang Sun; Jiayuan Hu; Chen Zhao; Ruijin Qiu; Xiaoyu Zhang; Qin Zhang; Guihua Tian; Hongcai Shang
Journal:  Front Pharmacol       Date:  2018-08-03       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.